**Specifications table**TableSubject area*Chemistry, biology*More specific subject area*Biomaterials*Type of data*Tables, Figures*How data were acquired*Static tensile mechanical testing (Instron5655), Mercury intrusion porosimeter (Quantachrome Poremaster 60GT), X-ray diffraction (XRD; Bruker D8 Advance), immunohistochemistry*Data format*Analyzed*Experimental factors*Scaffolds prior to implantation were subjected to uniaxial mechanical testing and mercury intrusion porosimeter. Scaffold explants at different time points were subjected to uniaxial mechanical testing and XRD characterized. In addition, explants were sectioned and stained for Hematoxylin and Eosin (H&E) and Masson׳s trichrome (M&T). Immunofluorescent staining was carried out to detect presence of capillary markers (i.e. CD31), macrophage markers (i.e. CD86, CD68, CD163) and T-cell makers (i.e. CD3, CD4).*Experimental features*Physico-mechanical characterization, histology and immunohistochemistry*Data source location*Centre for Biomaterials in Surgical Reconstruction and Regeneration, Division of Surgery & Interventional Science, University College London, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom, NW3 2PF*Data accessibility*Within this article*Related research article[@bib1]*L. Wu, A. Magaz, E. Maughan, N. Oliver, A. Darbyshire, M. Loizidou, M. Emberton, M. Birchall, W. Song, Cellular responses to thermoresponsive stiffness memory elastomer nanohybrid scaffolds by 3D-TIPS, Acta Biomater. (2018).*[doi:10.1016/j.actbio.2018.12.019](https://doi.org/10.1016/j.actbio.2018.12.019){#ir0005}.

**Value of the data**•Data presented in this article provide direct comparison of the stiffness softening and hierarchical structure of the 3D-TIPS scaffolds before and after *in vitro* and *in vivo* tests. The data magnify more insights about the changes of structures at multi-scales and mechanical properties of the scaffolds under biophysical and biological conditions.•The histological images of the scaffolds with different initial stiffness and porous structure by immunohistochemistry elucidate for the first time how the stiffness softening and digitally printed hierarchical porous structure regulate tissue ingrowth, vascularization and macrophage polarization towards an M2 phenotype at the early (week 4) and late (week 12) stages *in vivo*.

1. Data {#s0005}
=======

[Table 1](#t0005){ref-type="table"} shows the stiffness softening effect of the scaffolds *in vitro* over day 0--28 and how they relax towards their intrinsic elasticity. The dimensions of the 3D printed preforms and the scaffolds as produced are shown in [Table 2](#t0010){ref-type="table"}. [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"} show the effects of softening during *in vivo* implantation at various time points, in terms of tensile mechanical properties and XRD characterization respectively. [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"} depict low and high magnification of Hematoxylin and Eosin (H&E) and Masson׳s trichrome (M&T) staining showing collagen fibre orientation and tissue ingrowth within the explants. [Table 8](#t0040){ref-type="table"} quantifies the angiogenic response of the explants during implantation time with stiffness softening. The softening effects on macrophage polarization (M1 markers CD86, CD63 and M2 maker CD163) and T-cell response (markers CD3 and CD4) are quantified in [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"}; representative immunohistochemistry images are shown in [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"}, [Fig. 11](#f0055){ref-type="fig"}, [Fig. 12](#f0060){ref-type="fig"}, [Fig. 13](#f0065){ref-type="fig"}.

1.1. Static tensile mechanical properties and hierarchical porous structure of the scaffolds {#s0010}
--------------------------------------------------------------------------------------------

[Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}.Table 1Stiffness softening of PUU-POSS scaffolds with 50% infill density, tested at wet condition before and after *in vitro* incubation at 37${^\circ}C$ over 28 days.Table 1**3D-TIPS scaffold, 50% infillTensile Modulus (at 50% strain) MPaTensile Modulus (at 100% strain) MPaUltimate tensile strength (breaking point), MPaStrain at break, %Toughness, J** **m**^**−3**^**×** **10**^**4**^**50CC**Day 00.98 (±0.14)0.82 (±0.21)1.33 (±0.09)179 (±8)137 (±22)Day 280.45 (±0.08)0.40 (±0.11)0.77 (±0.15)230 (±13)115 (±20)**50CC+H**Day 00.53 (±0.02)0.44 (±0.08)0.76 (±0.05)236 (±19)113 (±27)Day 280.39 (±0.09)0.32 (±0.08)0.72 (±0.12)240 (±18)110 (±14)**50RTC+H**Day 00.44 (±0.06)0.39 (±0.09)0.67 (±0.03)146 (±15)146 (±12)Day 280.42 (±0.08)0.38 (±0.10)0.65 (±0.06)149 (±19)146 (±20)Table 2Dimensions of 3D-printed PVA preforms and PUU-POSS scaffolds made by 3D-TIPS.Table 2**Scaffoldx- Strut thickness (μm, *n*** **=** **10)y-Strut thickness (μm, *n*** **=** **10)z-Strut thickness (μm, *n*** **=** **10)Sample Size, (L×W×T, mm) (*n*** **=** **6)Apparent Volume (mm**^**3**^**)Volume Swelling Ratio vs V**~**PVA**~**(%)**50% infill PVA preform (mould)40040020060.0 × 12.0 × 4.02880 ± 4**50CC**Wet, as produced, RT197 ± 13157 ± 9118 ± 1961.0 × 13.0 × 3.62855 ± 9−0.9 ± 0.2**50CC+H**Wet, as produced, RT176 ± 8150 ± 8121 ± 1459.7 × 11.3 × 3.52361 ± 7−18.0 ± 0.1**50RTC+H**Wet, as produced, RT186 ± 10140 ± 11127 ± 1058.9 × 12.7 × 3.92917 ± 131.2 ± 0.3Table 3Tensile modulus (at 50% strain) of the scaffold explants at weeks 4, 8 and 12.Table 3**Tensile modulus (MPa)50CC50CC+H50RTC+H**Week 01.11 (±0.13)0.77 (±0.09)0.43 (±0.08)Week 42.45 (±0.40)2.13 (±1.38)1.56 (±0.20)Week 83.99 (±0.55)3.73 (±0.78)3.13 (±0.88)Week 126.97 (±1.46)6.08 (±1.35)5.88 (±1.53)Table 4Strain at break of the scaffold explants at weeks 4, 8 and 12.Table 4**Strain at break (%)50CC50CC+H50RTC+H**Week 0179 (±18)186 (±19)146 (±15)Week 4340 (±24)310 (±61)291 (±70)Week 8444 (±73)423 (±71)406 (±122)Week 12521 (±70)494 (±65)454 (±80)Table 5Ultimate tensile strength (breaking point) of the scaffold explants at weeks 4, 8 and 12.Table 5**Ultimate tensile strength (MPa)50CC50CC+H50RTC+H**Week 01.63 (±0.09)0.99 (±0.05)0.67 (±0.07)Week 41.07 (±0.39)1.01 (±0.45)0.81 (±0.18)Week 81.98 (±0.37)1.86 (±0.53)1.16 (±0.39)Week 122.84 (±0.53)2.60 (±0.75)2.44 (±0.29)Table 6Toughness of the scaffold explants at weeks 4, 8 and 12.Table 6**Toughness (J m^−3^ 10^4^)50CC50CC+H50RTC+H**Week 0137 (±12)146 (±12)113 (±17)Week 4412 (±24)370 (±66)351 (±79)Week 8523 (±73)463 (±81)406 (±162)Week 12599 (±99)524 (±77)444 (±90)Table 7Analysis of WAXD spectra of the explants during implantation. Degree of crystallinity (Dc, %), d-spacing (d, A) of semicrystalline structure and broad halo peaks of amorphous structures.Table 7**ScaffoldsWeek 0Week 4Week e8Week 122**$\mathbf{\theta}$**dDc2θdDc2θdDc2θdDc50CCSharp peak 1**20.04.437.6**Sharp peak 2**23.23.8**Broad halo peak 1Broad halo peak 2**20.1**Broad halo peak 3**30.030.531.2**Broad halo peak 4**40.541.541.9**50CC+HSharp peak 1Sharp peak 2Broad halo peak 1Broad halo peak 2**19.219.220.0**Broad halo peak 3**30.328.829.830.9**Broad halo peak 4**41.342.142.242.2**50RTC+HSharp peak 1Sharp peak 2Broad halo peak 1Broad halo peak 2**19.3**Broad halo peak 3**26.025.927.027.1**Broad halo peak 4**42.342.042.741.6

1.2. Cellular infiltration and matrix deposition {#s0015}
------------------------------------------------

[Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}.Fig. 1Hematoxylin & Eosin (H&E) stained histological structure of middle in-plane of 50CC scaffold explants at week 12 depicting tissue ingrowth within the scaffold network, ×2 magnifications.Fig. 1Fig. 2Subcutaneous implantation of 50CC+H scaffolds at week 12: (A) tissue integration of middle-in-plane of the 50CC+H scaffold by Hematoxylin and Eosin (H&E) staining, (B) collagen production by Masson׳s trichrome staining (M&T), (C) endothelial cell infiltration as identified by CD31 staining, used as a marker of angiogenesis; (D-F) enlarged views of middle-in-plane sections respectively. (G-I) Middle cross-sectional view and (J-L) enlarged middle cross-sectional view.Fig. 2Fig. 3Subcutaneous implantation of 50RTC+H scaffolds at week 12: (A) tissue integration of middle-in-plane of the 50RTC+H scaffold by Hematoxylin and Eosin (H&E) staining, (B) collagen production by Masson׳s trichrome staining, (C) endothelial cell infiltration as identified by CD31 staining, used as a marker of angiogenesis; (D-F) enlarged middle-in-plane views respectively. (G-I) Middle cross-sectional view and (J-L) enlarged middle cross-sectional view.Fig. 3

1.3. Angiogenesis response {#s0020}
--------------------------

[Table 8](#t0040){ref-type="table"}.Table 8Proportion of total tissue/scaffold volume occupied by blood capillaries at weeks 4, 8 and 12. Immunofluorescent staining of anti-CD31 marker for blood capillaries.Table 8**Capillary (%)50CC50CC+H50RTC+H**Week 411 (±1)6 (±2)3 (±2)Week 825 (±3)12 (±4)8 (±4)Week 1230 (±4)20 (±5)14 (±5)

1.4. T-cell proliferative and host macrophage response {#s0025}
------------------------------------------------------

[Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"}, [Fig. 11](#f0055){ref-type="fig"}, [Fig. 12](#f0060){ref-type="fig"}, [Fig. 13](#f0065){ref-type="fig"}.Table 9Host pan-macrophage/monocyte response (CD68+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm^2^) at week 4, 8 and 12 (*n* = 20 frames, 12 scaffolds in each group at each time point).Table 9**CD68+50CC50CC+H50RTC+H**Week 4353 (±54)301 (±56)210 (±46)Week 8322 (±48)260 (±39)164 (±48)Week 12228 (±39)201 (±43)115 (±52)Table 10Host macrophage response (CD86+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm^2^) at week 4, 8 and 12 (*n* = 20 frames, 12 scaffolds in each group at each time point).Table 10**CD86+50CC50CC+H50RTC+H**Week 4397 (±56)289 (±47)152 (±39)Week 8312 (±55)224 (±51)132 (±45)Week 12271 (±41)186 (±55)96 (±53)Table 11Host macrophage response (CD163+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffold per unit square (Nv/mm^2^) at week 4, 8 and 12 (*n* = 20 frames, 12 scaffolds in each group at each time point).Table 11**CD163+50CC50CC+H50RTC+H**Week 4360 (±64)294 (±65)78 (±36)Week 8531 (±88)434 (±76)103 (±67)Week 12679 (±94)534 (±78)167 (±46)Table 12Ratio of CD68+/ CD163+ of the various scaffold groups at weeks 4, 8 and 12.Table 12**CD68+/CD163+50CC50CC+H50RTC+H**Week 40.981.022.69Week 80.600.591.59Week 120.330.380.68Table 13Ratio of CD86+/ CD163+ of the various scaffold groups at weeks 4, 8 and 12.Table 13**CD86+/CD163+50CC50CC+H50RTC+H**Week 41.100.981.95Week 80.590.521.28Week 120.400.350.57Table 14Host T lymphocyte response (CD3+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffolds per unit square (Nv/mm^2^) at week 4, 8 and 12 (*n* = 20 frames, 12 scaffolds in each group at each time point).Table 14**CD3+50CC50CC+H50RTC+H**Week 4372 (±54)301 (±56)134 (±31)Week 8232 (±48)204 (±39)67 (±15)Week 12156 (±44)109 (±43)35 (±8)Table 15Host T lymphocyte response (CD4+ marker) towards the implanted scaffolds in terms of numerical density (Nv), representing the number of cells across the scaffolds per unit square (Nv/mm^2^) at week 4, 8 and 12 (*n* = 20 frames, 12 scaffolds in each group at each time point).Table 15**CD4+50CC50CC+H50RTC+H**Week 4301 (±61)245 (±71)152 (±27)Week 8252 (±42)201 (±46)102 (±28)Week 12122 (±32)87 (±45)32 (±16)Fig. 4Immunohistochemistry of the host macrophage response towards scaffolds *in vivo* at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD68 (M1 pan-macrophage/monocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.Fig. 4Fig. 5Immunohistochemistry of the host macrophage response towards scaffolds *in vivo* at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD68 (pan-macrophage/monocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-I) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm.Fig. 5Fig. 6Immunohistochemistry of the host macrophage response towards scaffolds *in vivo* at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD86 (M1 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.Fig. 6Fig. 7Immunohistochemistry of the host macrophage response towards scaffolds *in vivo* at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD86 (M1 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm.Fig. 7Fig. 8Immunohistochemistry of the host macrophage response towards scaffolds *in vivo* at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD163 (M2 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.Fig. 8Fig. 9Immunohistochemistry of the host macrophage response towards scaffolds *in vivo* at weeks 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD163 (M2 macrophage marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat liver). Scale bar: 100 μm.Fig. 9Fig. 10Immunohistochemistry of the host T lymphocyte response towards scaffolds *in vivo* at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD3 (T lymphocyte marker) staining at (A-C, G-L) ×4 and (D-F, J-L) ×40 magnifications.Fig. 10Fig. 11Immunohistochemistry of the host T lymphocyte response towards scaffolds *in vivo* at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD3 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat spleen). Scale bar: 100 μm.Fig. 11Fig. 12Immunohistochemistry of the host T lymphocyte response towards scaffolds *in vivo* at week 4. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD4 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications.Fig. 12Fig. 13Immunohistochemistry of the host T lymphocyte response towards scaffolds *in vivo* at week 12. Tissue integration of middle-in-plane (A-F) and cross-sectional view (G-L) of the scaffolds by CD4 (T lymphocyte marker) staining at (A-C, G-I) ×4 and (D-F, J-L) ×20 magnifications. (M) Negative control (rat appendix); (N) positive control (rat spleen). Scale bar: 100 μm.Fig. 13

2. Experimental design, materials and methods {#s0030}
=============================================

2.1. Fabrication of thermoresponsive PUU-POSS scaffolds {#s0035}
-------------------------------------------------------

A 3D-TIPS technique, based on reverse 3D printing and phase separation of the polymer solution, as described in [@bib1], was used to manufacture PUU-POSS scaffolds (50% infill density) at different thermal conditions (50CC, 50CC+H and 50RTC+H).

2.2. Characterization of the scaffolds prior to implantation {#s0040}
------------------------------------------------------------

An Instron 5655 was applied to test static tensile mechanical properties of the scaffolds, before and after incubation over 28 days at body temperature, as described in [@bib1], as well the explants after implantation in rats for 4, 8 and 12 weeks. The dimensions of the printed preforms and the scaffold as produced were also measured and estimated.

2.3. Characterization of the scaffold explants {#s0045}
----------------------------------------------

As detailed in [@bib1], the scaffolds were subcutaneously implanted in adult male rats and harvested at different time points. The physico-mechanical properties (i.e. tensile properties and phase structure) were then analyzed with an Instron 5655 tester and an X-ray diffractometer. Sectioning and histological staining (i.e. H&E and M&T) were carried out, and collagen fiber formation and tissue ingrowth orientation was quantified as previously described [@bib1]. Immunofluorescent staining against capillary marker CD31, macrophage markers CD86/CD68/CD163 and T-cell makers CD3/CD4 was carried out, and the number of positive stained cells was quantified as described in [@bib1].

Transparency document. Supplementary material {#s0060}
=============================================

Supplementary material..

The authors acknowledge financial support by the Engineering and Physical Sciences Research Council in the United Kingdom (EPSRC), grant Nos. EP/L020904/1, EP/M026884/1 and EP/R02961X/1.

Competing interests {#s0050}
===================

The authors declare no potential conflict of interests with respect to the research, authorship and/or publication of this article.

Transparency document associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2019.01.012>.

[^1]: Current address: Bio-Active Materials Group, School of Materials, The University of Manchester, Manchester, United Kingdom.
